Endologix has announced enrolment of the first patient in the company’s US clinical trial to evaluate the Ventana fenestrated stent graft system for the endovascular repair of juxtarenal and pararenal abdominal aortic aneurysms.
Aptus Endosystems, a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), has announced the start of ANCHOR, a global, multicentre, prospective post-market registry, which will evaluate the use of the HeliFX Aortic Securement System in the treatment of abdominal aortic aneurysms.
On 9 February, Endologix announced the completion of patient enrolment in the prospective, multicentre, randomised clinical trial of a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR).
A divided federal appeals court upheld a $371.2 million award in favor of C.R. Bard Inc in a long-running patent infringement dispute with W.L. Gore & Associates over vascular grafts. Reuters.
Boston Scientific announced the US launch of the TruePath CTO device, designed to facilitate the crossing of chronic total occlusions (CTOs) within the peripheral vasculature.
Medtronic has announced positive results at one-year follow-up of the Complete SE (selfexpanding) vascular stent study for the treatment of atherosclerosis in the superficial femoral artery (SFA).
Eurocor GmbH unveiled the first insights of the ongoing Freeway stent study during the Eurocor Symposium at Leipzig Interventional Course (LINC), Germany.
A new analysis from a two-year follow up of participants in the CREST (Carotid revascularization endarterectomy versus stenting) trial show that carotid artery stenting and carotid endarterectomy are equally effective at halting carotid restenosis in stroke prevention. Results of the analysis were detailed in a presentation at the American Stroke Association’s International Stroke Conference (%ew Orleans, USA, 1–3 February 2012).
Spectranetics announced six month interim results from the PATENT (Photo-ablation using the Turbo-Booster and excimer laser for in-stent restenosis treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis in the femoropopliteal artery in the leg.
Pulmonary embolism continues to be a major cause of morbidity and mortality in the United States. In most clinical situations, anticoagulation is the preferred form of therapy. The efficacy of inferior vena cava filters is still discussed controversially since several factors for effective pulmonary embolism prevention have to be considered.
Physicians at University Hospitals (UH) Case Medical Center, USA, enrolled their first patient in LEVANT 2, a global, multicentre, randomised clinical trial evaluating the safety and efficacy of the Moxy drug-coated balloon for the treatment of peripheral artery disease.
Cook Medical has launched its first drug-eluting balloon (DEB) approved to treat stenotic or occlusive disease in the peripheral vascular system. The Advance 18 PTX will be sold across Europe following CE mark approval in December 2011 after notification from Lloyds Register Quality Assurance, London.
Bard has acquired Lutonix for a purchase price of approximately US$225 million paid at closing, with an additional US$100 million to be paid upon US premarket approval of Lutonix’s drug-coated percutaneous transluminal angioplasty (PTA) balloon. The transaction was announced in December 2011 and is structured as a merger.
Medtronic announced the CE mark and international launch of the Endurant II AAA stent graft system for the treatment of abdominal aortic aneurysms through endovascular aortic repair (EVAR).
Nine-month clinical endpoint data from the ORION trial demonstrate excellent outcomes for the Epic self-expanding nitinol stent system (Boston Scientific) in patients with iliac artery disease. Results were presented by Daniel Clair, principal investigator of the trial and chairman of the Department of Vascular Surgery, The Cleveland Clinic Foundation, at the 24th International Symposium on Endovascular Therapy (ISET) in Miami, USA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos